Covered recipient · General Payments record
CHRISTINA A SAUREL
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$10,611.08
- Reported across 452 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,277.73 | 60 |
| Education | $42.09 | 3 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Celgene Corporation | $294.22 | 13 |
| PFIZER INC. | $151.69 | 9 |
| ABBVIE INC. | $101.97 | 5 |
| Daiichi Sankyo Inc. | $71.62 | 3 |
| Regeneron Healthcare Solutions, Inc. | $58.51 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $53.25 | 2 |
| Janssen Biotech, Inc. | $52.39 | 2 |
| Exelixis Inc. | $45.52 | 2 |
| Acerta Pharma LLC | $44.49 | 2 |
| GlaxoSmithKline, LLC. | $39.33 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $27.86 | 1 |
| Merck Sharp & Dohme Corporation | $27.43 | 1 |
| SOBI, INC | $27.32 | 1 |
| Tempus AI, Inc | $26.19 | 1 |
| ARRAY BIOPHARMA INC | $25.20 | 3 |
| Sumitomo Pharma America, Inc. | $24.81 | 1 |
| EISAI INC. | $24.69 | 1 |
| Incyte Corporation | $22.18 | 1 |
| Rigel Pharmaceuticals, Inc. | $21.02 | 1 |
| Myriad Genetic Laboratories, Inc. | $20.32 | 1 |
| Alexion Pharmaceuticals, Inc. | $19.72 | 1 |
| Immunocore Limited | $19.42 | 1 |
| E.R. Squibb & Sons, L.L.C. | $19.07 | 1 |
| Gilead Sciences, Inc. | $18.72 | 1 |
| Karyopharm Therapeutics Inc. | $18.46 | 1 |
| PharmaEssentia USA Corporation | $17.57 | 1 |
| RECORDATI_RARE_DISEASES_INC. | $17.26 | 1 |
| Agios Pharmaceuticals, Inc. | $15.98 | 1 |
| Genentech USA, Inc. | $13.61 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (63)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.